創薬開発のためのタンパク質発現リソース

抄録

Human protein research on the genomic scale is currently becoming more plausible to conduct due to the accumulation of both genome sequencing data1 and full-length cDNA clones. If many proteins are handled simultaneously, it is assumed that analysis of many reactions such as enzyme-substrate reactions, protein-protein interactions, protein modifications, processing by peptidases, etc., could be carried out more easily and effectively. In vitro proteome research, which handles expressed proteins on a large scale, has the advantage of being able to handle proteins that exist in a restricted fashion in vivo, such as proteins with tissue-specific, stage-specific or intrinsically rare expression. Recently we constructed both resources and an infrastructure for genomic scale protein expression with multi-use purpose. To build this foundation, we adopted the so-called Gateway technology, which can adequately handle multiple expression modes, and planned the accumulation of Gateway entry clones as key resources. We produced about 60,000 entry clones, including full-length ORF, processed ORF, and Domain ORF type. By using these resources, we search the new target for drug discovery (ex. protein-protein interaction ) and construct the screening system for inhibitor of protein-protein interaction. In this talk, we would like to introduce the importance of the construction of protein expression resources and infrastructure for genomic scale protein expression.